Funder
Vice-Chancellor for Research, Shiraz University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Alday PH, Doggett JS (2017) Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Dev Ther 11:273. https://doi.org/10.2147/dddt.s60973
2. Arab-Mazar Z, Fallahi S, Koochaki A, Haghighi A, Seyyed Tabaei SJ (2016) Immunodiagnosis and molecular validation of Toxoplasma gondii-recombinant dense granular (GRA) 7 protein for the detection of toxoplasmosis in patients with cancer. Microbiol Res 183:53–59. https://doi.org/10.1016/j.micres.2015.11.006
3. Asgari Q, Keshavarz H, Rezaeian M, Motazedian MH, Shojaee S, Mohebali M, Miri R (2013a) Direct effect of two naphthalene-sulfonyl-indole compounds on Toxoplasma gondii tachyzoite. J Parasitol Res. https://doi.org/10.1155/2013/716976
4. Asgari Q, Keshavarz H, Shojaee S, Motazedian MH, Mohebali M, Miri R, Rezaeian M (2013b) In vitro and in vivo potential of RH strain of Toxoplasma gondii (Type I) in tissue cyst forming. Iran J Parasitol 8(3):367
5. Bentley R, Haslam E (1990) The shikimate pathway—a metabolic tree with many branche. Crit Rev Biochem Mol Biol 25(5):307–384. https://doi.org/10.3109/10409239009090615